Preparation and Characterization of Coenzyme Q10 Powder Micronized by a Rapid Expansion of Supercritical Solution (RESS) Process

Abstract:

Micronized Coenzyme Q₁₀ (CoQ₁₀) is prepared with a rapid expansion of supercritical solution (RESS) process, which does not employ toxic organic solvent. Four factors, namely extraction pressure, extraction temperature, nozzle diameter and precipitation temperature are optimized by a four-level orthogonal array design. The optimum micronization conditions are determined as follows: extraction pressure 25 Mpa, extraction temperature 40°C, nozzle diameter 200 μm, and precipitation temperature 25°C. Under the optimum conditions, micronized CoQ₁₀ with a MPS of 147.9±27.3 nm is obtained. The micronized CoQ₁₀ obtained was characterized by High performance liquid chromatography-mass spectrometry (LC–MS) and High performance liquid chromatography (HPLC) analyses. The results showed that RESS micronization process does not induce degradation of CoQ₁₀ and the obtained CoQ₁₀ particles have higher dissolution rate and solubility compared with unprocessed CoQ₁₀ powder.

• Periodical: Advanced Materials Research (Volume 345)
• Pages: 53-59
• DOI: https://doi.org/10.4028/www.scientific.net/AMR.345.53
• Online since: September 2011
• Authors: Xiang Dong Meng, Yuan Gang Zu, Qing Yong Li, Xiu Hua Zhao, Shou Gang Jiang, Mei Sang
• Keywords: Characterization, Coenzyme Q₁₀, Micronization, Nanosuspension, Preparation, Rapid Expansion of Supercritical Solution

References

[1] G. Grossi, A.M. Bargossi, P.L. Fiorella, S. Piazzi, M. Battino and G.P. Bianchi: J. Chromatogr. Vol. 593 (1992), pp.217-226.

DOI: 10.1016/0021-9673(92)80289-7

[2] J. Hojerova: Ceska a Slovenska Farmacie. Vol. 49 (2000), pp.119-123.

[3] F.L. Crane: J. American College of Nutrition. Vol. 20 (2001), pp.591-598.

[4] D.D. Ankola, B. Viswanad, V. Bhardwaj, P. Ramarao and M.N. Kumar: Eur J Pharm Biopharm. Vol. 67 (2007), pp.361-369.

[5] W.C. Lee and T.H. Tsai: Int J Pharm. Vol. 395 (2010), pp.78-83.

[6] J. Zhang and S. Wang: Int J Pharm. Vol. 372 (2009), pp.66-75.

[7] V. Teeranachaideekul, E.B. Souto, V.B. Junyaprasert and R.H. Müller: Eur J Pharm Biopharm. Vol. 67 (2007), pp.141-148.

[8] J. Pardeike, K. Schwabe and R.H. Müller: Int J Pharm. Vol. 396 (2010), pp.166-173.

[9] S.S. Kwon, Y.S. Nam, J.S. Lee, B.S. Ku, S.H. Han, J.Y. Lee and I.S. Chang: J Colloids Surf A. Vol. 210 (2002), pp.95-104.

[10] B.J. Nehilla, M. Bergkvist, K.C. Popat and T.A. Desai: Int J Pharm. Vol. 348 (2008), pp.107-114.

[11] P.R. Nepal, H.K. Han and H.K. Choi: Int J Pharm. Vol. 383 (2010), pp.147-153.

[12] B.K. Kang, S.J. Lee, S.K. Chon, S.Y. Jeong, S.H. Yuk, G. Khang, H.B. Lee and S.H. Cho: Int J Pharm. Vol. 274 (2004), pp.65-73.

[13] A. Palamakula and M.A. Khan: Int J Pharm. Vol. 273 (2004), pp.63-73.

[14] T.R. Kommuru, B. Gurley, M.A. Khan and I.K. Reddy: Int J Pharm. Vol. 212 (2001), pp.233-246.

[15] K. Byrappa, S. Ohara and T. Adschiri: Adv Drug Deliv Rev. Vol. 60 (2008), pp.299-327.

[16] VB Patravale, AA Date and RM Kulkarni: J Pharm Pharmacol. Vol. 56 (7) (2004), pp.827-840.

[17] J.S. Kim, M.S. Kim, H.J. Park, S.J. Jin, S. Lee and S.J. Hwang: Int J Pharm. Vol. 359 (2008), pp.211-219.

[18] M.S. Kim, S.J. Jin, J.S. Kim, H.J. Park, H.S. Song, R.H. Neubert and S.J. Hwang: Eur J Pharm Biopharm. Vol. 69 (2008), p.454–465.